Citi downgraded Sarepta Therapeutics to Neutral from Buy with a price target of $176, up from $172. After the 30% rally post-FDA approval and label expansion of Elevidys, Sarepta is now appropriately valued, the analyst tells investors in a research note. While some sell-siders have argued for valuations of $200-plus per share, Citi’s modeling suggests a fair value of no greater than $180, the firm points out. It believes the shares “could grind higher on incremental positive news,” but sees a lack of material near-term catalysts until readout of Phase 3 ENVISION study in non-ambulatory in 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Planet Fitness upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Sarepta price target raised to $185 from $139 at Evercore ISI
- Sarepta price target raised to $200 from $170 at BMO Capital
- Sarepta price target raised to $230 from $165 at Leerink
- Sarepta price target raised to $200 from $165 at Morgan Stanley